A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.
Sign Up to like & getrecommendations! Published in 2017 at "Cell reports"
DOI: 10.1016/j.celrep.2017.07.006
Abstract: Combinatorial inhibition of effector and feedback pathways is a promising treatment strategy for KRAS mutant cancers. However, the particular pathways that should be targeted to optimize therapeutic responses are unclear. Using CRISPR/Cas9, we systematically mapped… read more here.
Keywords: mutant cancers; therapeutic cooperativity; landscape therapeutic; cancers reveals ... See more keywords
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers
Sign Up to like & getrecommendations! Published in 2024 at "Proceedings of the National Academy of Sciences of the United States of America"
DOI: 10.1073/pnas.2319492121
Abstract: Significance KRASG12C inhibitors have shown clinical responses in KRASG12C-mutant lung cancer, but much less so in colon cancers having the same mutation. In lung cancer, acquired resistance limits the clinical benefit patients experience. Here, we… read more here.
Keywords: kras mutant; molecule inhibition; mutant cancers; small molecule ... See more keywords
BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers
Sign Up to like & getrecommendations! Published in 2019 at "Science Advances"
DOI: 10.1126/sciadv.aax1738
Abstract: BAP1 regulates developmental switch in lineages commonly affected by BAP1-mutant cancers. The BAP1 tumor suppressor is mutated in many human cancers such as uveal melanoma, leading to poor patient outcome. It remains unclear how BAP1… read more here.
Keywords: mutant cancers; bap1 regulates; bap1; switch ... See more keywords
Abstract B142: EO3001: A novel agent for ARID1A mutant cancers
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-25-b142
Abstract: ARID1A mutations are among the most common genetic alterations in cancer, occurring in approximately 65% of ovarian clear cell carcinoma (OCCC) and up to 10% of all solid tumors. These mutations disrupt chromatin remodeling and… read more here.
Keywords: arid1a mutant; cancer; agent; eo3001 ... See more keywords
Abstract CT178: Phase 1 trial of PF-07799933 (ARRY-440), a next-generation BRAF inhibitor, for BRAF-mutant cancers
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-ct178
Abstract: BACKGROUND Approved BRAF inhibitors (BRAFi) have transformed the treatment of BRAF V600-mutant cancers. However, clinical benefit is limited by BRAF dimer-promoting resistance mutations, toxicity from paradoxical activation of signaling in BRAF wild-type cells, and poor… read more here.
Keywords: cancer; braf; next generation; mutant cancers ... See more keywords
Abstract 483: RNA-missplicing dependent nucleic acid therapeutics for SF3B1-mutant cancers
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-483
Abstract: Cancer therapies face the challenge of specificity-limiting toxicity to normal cells and maximizing it in malignant ones. The last two decades have seen significant advancements in therapeutics that increase specificity; however, these remain elusive for… read more here.
Keywords: nucleic acid; specificity; sf3b1 mutant; acid therapeutics ... See more keywords
Abstract 6896: A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-6896
Abstract: KRAS mutations are highly prevalent in a wide range of lethal cancers, and these mutant forms of KRAS play a crucial role in driving cancer progression and conferring resistance to treatment. While there have been… read more here.
Keywords: cancer; treatment kras; kras degrader; kras mutant ... See more keywords
Abstract A010: Using oncogenic pathway agonism to sensitize RAS-mutant cancers to immunotherapy
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Cancer Research"
DOI: 10.1158/1557-3125.ras23-a010
Abstract: Overall, some 30% of human cancers are driven by mutant RAS proteins, which have proven relatively difficult to target. While immunotherapy is effective for NRAS-mutant melanoma, no options exist for resistant disease, and mutant KRAS-driven… read more here.
Keywords: oncogenic pathway; ras mutant; sensitize ras; pathway agonism ... See more keywords
(R)-2-hydroxyglutarate inhibits KDM5 histone lysine demethylases to drive transformation in IDH-mutant cancers.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-22-0825
Abstract: Oncogenic mutations in isocitrate dehydrogenase (IDH)-1 and -2 occur in a wide range of cancers, including acute myeloid leukemia (AML) and glioma. Mutant IDH enzymes convert 2-oxoglutarate (2OG) to (R)-2-hydroxyglutarate ((R)-2HG)), an oncometabolite that is… read more here.
Keywords: idh mutant; histone lysine; idh; mutant cancers ... See more keywords
Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Biomedical Science"
DOI: 10.1186/s12929-024-01060-3
Abstract: KRAS mutations frequently occur in cancers, particularly pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. Although KRASG12C inhibitors have recently been approved, effective precision therapies have not yet been established for all KRAS-mutant… read more here.
Keywords: tak 981; cancer; sumoylation; inhibition ... See more keywords
Non-Oncogene Addiction of KRAS-Mutant Cancers to IL-1β via Versican and Mononuclear IKKβ
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15061866
Abstract: Simple Summary Kirsten rat sarcoma virus (KRAS)-mutant cancers are frequent, metastatic, lethal, and largely undruggable. The aim of this study was to investigate the pathways through which KRAS-mutant cancers foster their growth, thereby unravelling novel… read more here.
Keywords: non oncogene; kras mutant; mutant cancers; addiction ... See more keywords